Our ambition

Maintaining our customers’ trust, by remaining a leading supplier and by meeting increasingly stringent quality standards, in both technological and environmental terms.

Indicadores claves

Más del 900 empleados
3 plantas de producción en todo el mundo (Montpellier, Kioto y San Pablo)
Más del 8% de los ingresos destinados a la investigación

01/08/2020 - HORIBA Medial launches QSP 2.0: Additional Empowerment to Laboratories for Skills Evaluation & Training in Hematology!

01/08/2020 - QSP 2.0: An Affordable Digital tool for “Skills Evaluation & Training” in blood morphology

HORIBA Medical and CEA-Leti renew their partnership for tomorrow's diagnostic technologies development.

21/07/2020 - HORIBA Medical and CEA-Leti strengthen their partnership to develop tomorrow’s diagnostics at the point of care.

21/07/2020 - Montpellier and Grenoble, France, July 21, 2020 HORIBA Medical, a subsidiary of Japan-based HORIBA...

15/07/2020 - HORIBA Medical has established a partnership with BioMedica to enlarge the scope in hemostasis from routine panel to specialties

15/07/2020 - HORIBA Medical has established a partnership with BioMedica Diagnostics Inc. (BMD)

Our ambition

Indicadores claves

01/08/2020 - HORIBA Medial launches QSP 2.0: Additional Empowerment to Laboratories for Skills Evaluation & Training in Hematology!

21/07/2020 - HORIBA Medical and CEA-Leti strengthen their partnership to develop tomorrow’s diagnostics at the point of care.

15/07/2020 - HORIBA Medical has established a partnership with BioMedica to enlarge the scope in hemostasis from routine panel to specialties

12/05/2020 - CORONAVIRUS [Covid19]

05/05/2020 - Multiphysics modelling, supporting research and development into new hematology devices at HORIBA Medical